НТНикита Сергеевич Титов

Никита Сергеевич Титов

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Никита Сергеевич Титов has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    MULTIDISCIPLINARY APPROACH TO TREATMENT OF PATIENT WITH BIOPROSTHETIC AORTIC VALVE DYSFUNCTION AND RENAL CELL CARCINOMA WITH TUMOR THROMBUS

    by Bagrat G. Alekyan, Alexander A. Gritskevich, Narek G. Karapetyan, Алина Андреевна Чевина, Евгений Васильевич Токмаков, Lilit H. Gyoletsyan, Zholboldu Polotbek Uulu, Artur V. Galstyan, Никита Сергеевич Титов, Marina V. Grigoryan, et al.

    HighlightsThis review presents a clinical case of a patient with a rare combination of two life-threatening pathologies whose treatment required high-tech surgery. The effectiveness of a multidisciplinary approach to treatment has been demonstrated. AnnotationAortic stenosis (AS) is the most common heart disease in elderly patients requiring treatment. Malignant neoplasms of the kidneys account for about 3% of all cancers in the Russian Federation, and the formation of tumor thrombi in the renal and inferior vena cava occurs in 4–10% of patients with this pathology. Given the prevalence of aortic stenosis and renal cell carcinoma (RCC), the number of patients with a combination of these two conditions keeps increasing and they are recommended to undergo surgical treatment at multidisciplinary clinical centers. Transcatheter aortic valve implantation (TAVI) and radical nephrectomy with intracorporeal thrombectomy using the DaVinci Si robotic surgical system may be a preferred approach for the treatment of critical AS and RCC for this category of patients.At the multidisciplinary clinical center a patient with dysfunctional bioprosthetic aortic valve implanted in 2010 and NYHA class 3 heart failure with history of endovascular treatment of coronary artery disease, peripheral arterial disease and carotid endarterectomy and concomitant renal cell carcinoma with tumor thrombosis of the renal vein received surgical treatment in 2 stages: TAVI – the first stage, and robot-assisted right-sided nephrectomy and thrombectomy from the renal vein – the second stage. The patient was discharged from the Center on the 7th day after TAVI and on the 6th day after surgery for renal cancer. Six months after the procedure, there was a decrease in the functional class of heart failure, satisfactory function of the transcatheter aortic valve bioprosthesis, decrease in the size of the left ventricle, decrease in the brain natriuretic peptide, and the absence of cancer progression.

  • Open Access

    Endovascular treatment of aortic valve stenosis in combination with coronary artery disease: a systematic review

    by B.G. Alekian, N.S. Titov

    Objective: To evaluate and compare the efficacy and safety of simultaneous and staged techniques of percutaneous coronary interventions (PCI) and transcatheter aortic valve implantation (TAVI). Methods: The search for sources was carried out in the PubMed, Google Scholar and Cochrane Library databases using keywords. We selected the most cited studies on strategies for endovascular treatment of patients with coronary artery disease and aortic stenosis with the focus on simultaneous and staged techniques of PCI and TAVI. Most attention has been paid to indicators of survival, complications and other study endpoints. The significance of the order of the interventions on patient outcomes was assessed. Results: Searching with keywords in the selected databases revealed 1,527 original sources and 60 of them were taken into the review. The selected sources included prospective and retrospective studies as well as the latest guidelines of professional societies on cardiovascular diseases, statistics of surgical interventions and morbidity, and basic researches. In approximately 70% of cases, a staged technique was used with initial putting into practice of PCI followed by TAVI. Most studies comparing selected techniques did not reveal a significant difference in endpoints; at the hospital period their frequency was usually within 3%, and at the long-term period they reached 30%. Nevertheless, a detailed analysis of the frequency of certain control points revealed contradictions in a number of studies.Conclusion: Despite intensive research into the effects of simultaneous and staged techniques of PCI and TAVI, the point of which approach is better remains disputable. The order of interventions is not reflected in current guidelines, majority of studies are retrospective, and their conclusions are ambiguous. Additional prospective studies are needed to determine the categories of patients who will benefit most from a particular order of PCI and TAVI. Received 9 April 2024. Revised 19 May 2024. Accepted 2 July 2024. FundingThe study did not have sponsorship. Conflict of interestThe authors declare no conflict of interest. Contribution of the authors The authors contributed equally to this article.


  • Open Access

    A clinical case of successful simultaneous percutaneous coronary intervention and endovascular mitral valve repair “edge-to-edge” with the MitraClip G4 device

    by B. G. Alekyan, N. G. Karapetyan, M. A. Saidova, M. V. Kadyrova, M. G. Grigoryan, N. N. Meleshenko, L. G. Gyoletsyan, N. S. Titov

    Mitral regurgitation is one of the prevalent entities among valvular defects in the adult population. In approximately half of the patients, the etiology of this defect is directly related to obstructive coronary artery disease. As a rule, the high perioperative risk in such patients is the main reason for the refusal to perform traditional open interventions. According to the available literature, the first experience of successful simultaneous percutaneous coronary intervention and transcatheter mitral valve repair “edge-to-edge” with the MitraClip G4 device is presented in a 77-year-old patient with severe mitral regurgitation who had previously suffered myocardial infarction and paroxysmal atrial fibrillation. The advantages of such an approach to treatment are demonstrated, and the need for its further study for systemic implementation is actualized.

  • Open Access

    EXPERIMENTAL IMMUNOTHERAPY MODEL OF RETINOBLASTOMA

    by T. L. Ushakova, I. S. Dolgopolov, Z. A. Sokolova, G. Z. Chkadua, N. S. Titov, Yu. M. Bukreev, Yu. A. Serov, O. V. Gorovtsova, D. A. Buletov, N. A. Kozlov, et al.

    Introduction. The main reason for enucleation of the eye when attempting organ-preserving treatment are intraocular tumors that do not respond well to chemotherapy.Purpose. The aim of the study was to find new effective and safe organ-preserving methods of treatment of intraocular refractory and recurrent retinoblastoma (RB).Materials and methods. The study included female chinchilla rabbits. The cell line of human RB was intravitreally inserted into the right eye of each animal. The left eye was a control. After obtaining a stable intraocular growth of RB and prolongation of the growth of RB, human cytotoxic lymphocytes (CTL) were intravitreally injected into the affected and control eye K1 at a concentration of 1 × 106 in 0.1 ml suspension and K2 – 5 × 106 in 0.1 ml, respectively.Results. Histological examination of the removed right eyes in animals confirmed the presence of nodal growth of malignant small-cell tumor on the border of the vascular and retinal membranes (epicenter in the choroid) on the posterior wall of the eye. There was scant lymphoid infiltration, without signs of therapeutic pathomorphosis. In the removed animal»s left eyes there is a preservation of histological structures of the eyeball, without dystrophic changes in the cells of the retina and vascular membranes. In the area of limb unit microcap lymphohistiocytic infiltration (with no elements of the tumor). In the choroid single scattered lymphocytes.Conclusion. A short period of observation of the tumor did not allow conclusions about the effectiveness of CTL, but the concentrations of CTL used in the experiment did not lead to dystrophic changes in retinal cells and the choroid of the eye, which is an important factor in overcoming the toxicity of the proposed adoptive immunotherapy. At the next stage of the experiment, in our opinion, it is necessary to study in more detail the cytotoxic effect on healthy structures of the eye and the effectiveness of CTL in a larger number of affected rabbit eyes, using their different concentrations and multiplicity of administration.